Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v6-EN | Version v2-FR | |
---|---|---|
Language | English | French |
Date Updated | 2020-04-09 | 2020-03-19 |
Drug Identification Number | 02245248 | 02245248 |
Brand name | AMIODARONE HYDROCHLORIDE INJECTION | AMIODARONE HYDROCHLORIDE INJECTION |
Common or Proper name | Amiodarone Hydrochloride | Amiodarone Hydrochloride |
Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
Ingredients | AMIODARONE HYDROCHLORIDE | AMIODARONE HYDROCHLORIDE |
Strength(s) | 50MG | 50MG |
Dosage form(s) | SOLUTION | SOLUTION |
Route of administration | INTRAVENOUS | INTRAVENOUS |
Packaging size | 50 mg/mL, MD Vial 3 mL | 50 mg/mL, MD Vial 3 mL |
ATC code | C01BD | C01BD |
ATC description | ANTIARRHYTHMICS, CLASS I AND III | ANTIARRHYTHMICS, CLASS I AND III |
Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
Anticipated start date | 2020-03-19 | 2020-03-19 |
Actual start date | ||
Estimated end date | 2020-03-31 | 2020-03-31 |
Actual end date | 2020-04-08 | |
Shortage status | Resolved | Anticipated shortage |
Tier 3 Status | No | No |
Company comments | Wednesday, April 8, 2020* On 100% Allocation | Fresenius Kabi Canada Ltd. regrets to advise that due to a delay in production we will be encountering a supply interruption on our Amiodarone Hydrochloride for Injection, 50 mg/mL, 3 mL Vial. Please note that replenishment inventories of this product have been received and are currently being evaluated by our Quality Assurance team for release as per standard process. This inventory is expected to be available to the market by March 31st, 2020. |
Health Canada comments |